Annual report and accounts

RNS Number:2415R
Research Pharmaceutical SRV, Inc
01 April 2008

1 April 2008

        ReSearch Pharmaceutical Services, Inc. ("RPS" or the "Company"))

          Despatch of Chairman's Letter and Form 10-K to Shareholders

RPS announces that it is today sending copies of its Form 10-K for the year to
December 31, 2007 to shareholders. Enclosed with the Form 10-K will be a letter
from Daniel M Perlman, Chairman and CEO, the text of which is set out below:

"RPS is pleased to report a very strong year, both financially and operationally
in 2007.

Over the last ten years, our business plan has been implemented and our growth
during this time is evidence that the unique model that RPS has developed and
brought to market has been widely accepted in the pharmaceutical / biotech
industry. We envisioned a radical change in the way that pharmaceutical
companies approached outsourcing their drug development needs and therefore an
alternative to traditional outsourcing was needed that addressed the critical
needs of the industry to contain costs, improve development speed and quality,
and importantly allow pharmaceutical companies to retain strategic control and
direction over their development pipeline and attendant clinical trials. Based
upon this vision, we began the creation of our new model, the "Next Generation
in the Evolution of CROs" that leverages the core competencies, systems and
processes of pharmaceutical companies and provides a mechanism to flexibly
expand their development capacity without adding permanent headcount. The
ultimate outcome of this unique service model is a reduction in total R&D
expenditures along with increased development speed and improved quality.

Over the last two years we have continued to evolve the RPS business model and
expanded its application to new pharmaceutical clients as well as increased
penetration and integration cross-functionally into existing clients. Our strong
revenue growth shows quantitative evidence of the model's acceptance by pharma
companies. In 2006 our service revenues increased 34.4% over 2005 service
revenues; in 2007 our service revenues increases 42.7% over 2006 service
revenues. We are very pleased with this rate of growth as it demonstrates that
our vision was, and remains on target with addressing the needs of the industry.

As our business plan continues to evolve, we plan to roll out our model on a
global basis to address the trend of expanding clinical trials globally. In this
regard, we have already successfully expanded our service offerings throughout
the Americas, including Canada and Latin America. In the future, we have set our
sights on further global expansion into Europe, India and China. Our business
plans include the continued build out and growth of our clinical capabilities
that will provide unique capabilities in support of small and mid size
bio-pharmaceutical companies.

In 2007 we completed our merger with a publicly held company trading on the
Alternative Investment Market (AIM) of the London Stock Exchange. As a result of
this transaction, we solidified our balance sheet by eliminating virtually all
outstanding debt while providing additional capital to execute our global
expansion plans and facilitate other critical strategic opportunities.
Additionally, in December 2007 we filed a registration statement with the SEC
and became an SEC reporting company in February 2008. The accompanying filing is
our first annual report.

The progress we have made as a company was enabled by the underlying support of
our employees throughout the Americas. They are hard working, caring individuals
and dedicated supporters of our model and our clients' drug development efforts.
Frankly, they are the best!!!! I would like to thank them for being the
foundation of our success to date.

Our success and accomplishments are also built upon strong relationships with
our customers. We are thankful to them for their ongoing trust and confidence
and to our shareholders for being supportive as we take our company into the
next phase of its growth.

Daniel M. Perlman,
Chairman and CEO"

Copies of the Form 10-K and letter from the Chairman and CEO will be available
on the Company's website, www.rpsweb.com.

For further information please contact:
ReSearch Pharmaceutical Services, Inc. [phone]
Dan Perlman, CEO
Steven Bell, Chief Financial Officer

Nominated Adviser and UK Broker:
Arbuthnot Securities Limited
James Steel / Richard Tulloch [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCUAVBRWRROOAR